Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential

Article summary

Incyte to acquire Vega Therapeutics for $1.25 billion upfront, adding a rare bleeding disorder candidate with blockbuster potential in 2030s.